Novavax, Inc.

Healthcare

NASDAQ:NVAX · NASDAQ Global Select

Market Cap $1.50B Beta 2.41 P/E (TTM) -17.3

$9.13 -1.84%

-$0.18 today

52W Low $6.13High $11.97

Vol 7.51M · Avg 4.58M

EPS (TTM) -$0.54Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+44.69%

Period High

$11.19

Period Low

$6.22

Latest

$9.13

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Terns Pharmaceuticals, Inc.

TERN

$4.77B

Trevi Therapeutics, Inc.

NASDAQ:TRVI

$2.40B

Intellia Therapeutics, Inc.

NASDAQ:NTLA

$1.71B

Precigen, Inc.

NASDAQ:PGEN

$1.40B

Nektar Therapeutics

NASDAQ:NKTR

$1.17B

Wave Life Sciences Ltd.

NASDAQ:WVE

$1.17B

CureVac N.V.

CVAC

$1.05B

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$883.00M

Zenas BioPharma, Inc.

NASDAQ:ZBIO

$858.99M

Upstream Bio, Inc.

NASDAQ:UPB

$337.68M

What is the latest NVAX filing?

The latest filing shown is SC 13D/A dated May 15, 2026.

How many recent filings does NVAX have?

Intrinsic Alpha currently shows 20 recent filings for NVAX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.